Avalyn Pharma expands Boston office lease space

Avalyn Pharma Inc. entered into a First Amendment to its sublease with CRISPR Therapeutics, expanding its Boston headquarters space at 105 West First Street.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Avalyn Pharma Inc. entered into a First Amendment to its sublease with CRISPR Therapeutics, expanding its Boston headquarters space at 105 West First Street.

The leased premises increase from approximately 8,774 to 13,708 rentable square feet as of June 29, 2026. Future minimum lease payments will rise by about $924,000 over the remaining lease term, while all other sublease terms remain in effect.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Original leased space: 8,774 rentable sq ft Expanded leased space: 13,708 rentable sq ft Increase in space: 4,934 rentable sq ft +2 more

5 metrics

Original leased space 8,774 rentable sq ft Premises under original sublease at 105 West First Street

Expanded leased space 13,708 rentable sq ft Premises after First Amendment effective June 29, 2026

Increase in space 4,934 rentable sq ft Difference between amended and original premises

Increase in future lease payments $924,000 Additional future minimum lease payments over remaining lease term

Effective Date of amendment June 29, 2026 Date First Amendment to Sublease became effective

Key Terms

Material Definitive Agreement, Sublease Amendment, future minimum lease payments, Emerging growth company

4 terms

Material Definitive Agreement regulatory

"Item 1.01 Entry into a Material Definitive Agreement."

A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.

Sublease Amendment financial

"entered into a First Amendment to the Sublease (the “Sublease Amendment”)"

future minimum lease payments financial

"the Company’s future minimum lease payments will increase by approximately $924,000"

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Avalyn Pharma Inc. (AVLN) change in its Boston lease?

Avalyn Pharma amended its sublease for office space in Boston, expanding the leased premises and increasing future minimum lease payments. The change reflects a larger footprint at 105 West First Street under its agreement with CRISPR Therapeutics.

How much additional space did Avalyn Pharma (AVLN) lease in Boston?

Avalyn Pharma expanded its leased premises from about 8,774 to 13,708 rentable square feet, an increase of roughly 4,934 square feet. This larger space remains within the same building at 105 West First Street in Boston, Massachusetts.

How will Avalyn Pharma’s (AVLN) lease amendment affect future payments?

Under the sublease amendment, Avalyn Pharma’s future minimum lease payments will increase by approximately $924,000 over the remaining lease term. This higher commitment corresponds to the expanded rentable square footage in the Boston premises.

Who is Avalyn Pharma’s sublandlord under the amended sublease?

Avalyn Pharma’s sublandlord is CRISPR Therapeutics, Inc. The First Amendment to the Sublease Agreement between Avalyn as subtenant and CRISPR Therapeutics as sublandlord governs the expanded space and increased lease payment obligations.

When did Avalyn Pharma’s amended sublease become effective?

The First Amendment to Avalyn Pharma’s sublease became effective on June 29, 2026. From this effective date, the rentable square footage increased and the revised future minimum lease payment schedule applies for the remaining lease term.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/01/2026 - 05:20 PM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): June 29, 2026

    

Avalyn Pharma Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-43251	45-2463191
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

105 W First Street
Boston, Massachusetts		02127
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: (206) 707-0340

    

     Not Applicable

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Voting Common Stock, par value $0.001 per share	AVLN	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On June 29, 2026 (the “Effective Date”), Avalyn Pharma Inc. (the “Company”) entered into a First Amendment to the Sublease (the “Sublease Amendment”), which amends that certain Sublease Agreement (the “Sublease Agreement”) with CRISPR Therapeutics, Inc. (the “Sublandlord”), dated as of August 29, 2025, providing for the lease of approximately 8,774 rentable square feet in the building located at 105 West First Street, Boston, Massachusetts (the “Premises”).

Pursuant to the Sublease Amendment, the Sublandlord and the Company, as Subtenant, have agreed to an expansion of the Premises from approximately 8,774 rentable square feet to approximately 13,708 rentable square feet as of the Effective Date.

Additionally, under the terms of the Sublease Amendment, the Company’s future minimum lease payments will increase by approximately $924,000 over the remaining lease term.

Except as modified by the Sublease Amendment, the terms of the Sublease Agreement remain in full force and effect.

The foregoing summary of the material terms of the Sublease Amendment does not purport to be a complete description and is qualified in its entirety by reference to the complete text of the Sublease Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number		Description
10.1		First Amendment to Sublease Agreement, by and between the Registrant and CRISPR Therapeutics, Inc., dated June 29, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			Avalyn Pharma Inc.

Date:	July 1, 2026	By:	/s/ Lyn Baranowski
			Lyn Baranowski Chief Executive Officer (Principal Executive Officer)

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents

Agreements & Contracts

EX-10.1 EX-10.1 59.7 KB